Why Zevra Therapeutics Stock Zoomed 21% Higher Today

Core Insights - Zevra Therapeutics experienced a significant stock price increase of over 21% following its latest earnings release, indicating strong investor interest [1] Financial Performance - The company reported net revenue of slightly over $34 million for Q4 2025, which is a 44% increase compared to the same period in 2024 [2] - Zevra achieved a net profit of $12.2 million ($0.19 per share) under GAAP, a turnaround from a loss of $35.7 million in the previous year [2][4] Product Success - The substantial revenue growth is largely attributed to the success of Miplyffa, a treatment for Niemann-Pick disease, with net sales increasing nearly ninefold to over $87 million during the quarter [5] - Miplyffa's market penetration has expanded significantly, reaching 68% of covered lives [5] International Expansion - Zevra has filed a marketing authorization application for Miplyffa with the European Medicines Agency, indicating potential for growth in international markets [6]